Medical Devices

Beyond the trade show floor, Chenwei Medical is executing a calculated strategy to fuse advanced critical care tech with deep clinical expertise in Latin America.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?

Alexandria Real Estate's top WSJ ranking for talent readiness reveals a new playbook where human capital is the most valuable asset, even in real estate.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

A new partnership between AI consultancy Toboggan Labs and research giant Mila aims to solve a critical problem: turning cutting-edge AI into real-world medical tools.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Johnson & Johnson's massive investment in Jacksonville promises economic growth, but the real story is a strategic pivot to secure the U.S. healthcare supply chain.

For 20 years, Montreal's Segal Cancer Centre has quietly built a world-class innovation engine. We dissect its unique model where research, care, and funding converge.

A new partnership between Argonaut and Ensera aims to untangle complex supply chains for drug-device products, potentially leveling the field for smaller innovators.

While biopharma braces for Medicare price negotiations, Halozyme claims immunity. Is its tech-licensing model the new blueprint for resilience or just a loophole?

One company's focus on convenience just earned it top marks. We explore how streamlined ordering and tech-savvy verification are reshaping the vision care industry.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

With exploration complete, new state laws in place, and a fortified land position, Pulsar Helium is fast-tracking its Topaz project to production.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Abbott's 410th dividend isn't just about shareholder returns. It’s a signal of the financial stability fueling a vast, invisible network of health tech.

Australian biotech Gelteq has a gel that makes bitter medicine taste good to dogs. It's more than a pet owner's dream—it's a strategic move in a $47B market.

A Chicago jury's landmark verdict reveals how a single day's delay can lead to a lifetime of paralysis, questioning the very fabric of patient safety.